Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clostebol is a synthetic anabolic–androgenic steroid (AAS) and the 4-chloro derivative of the natural hormone testosterone. The addition of a chlorine atom at the fourth position prevents its conversion to dihydrotestosterone (DHT) and estrogen. Clostebol acts as a weak AAS by binding to androgen receptors in muscle cells, promoting protein synthesis and muscle fiber repair. It also enhances nitrogen retention for anabolism and stimulates erythropoietin production to boost oxygen-carrying capacity. Medically, it has been used to treat conditions such as osteoporosis, anorexia, certain liver diseases, muscle wasting disorders, androgen deficiency states like delayed puberty in males, and minor skin wounds (often as topical esters). Clostebol is banned by the World Anti-Doping Agency due to its potential use as a performance-enhancing drug[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clostebol.